Summary
Boston Scientific Corporation (BSX) has filed a Form 8-K to report its financial results for the second quarter ended June 30, 2025. The company issued a press release on July 23, 2025, which contains these results and is furnished as an exhibit to this filing. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance, operational highlights, and forward-looking statements. While the 8-K itself does not contain the specific financial figures, it formally announces the release of this information. The content of the press release is not considered "filed" for regulatory purposes under Section 18 of the Exchange Act, but it serves as the primary source of information regarding BSX's Q2 2025 performance. Investors are encouraged to review the linked press release for a comprehensive understanding of the company's recent financial condition and results of operations.
Key Highlights
- 1Boston Scientific (BSX) announced its second quarter 2025 financial results via a press release on July 23, 2025.
- 2The 8-K filing serves as notification of the release of these Q2 2025 financial results.
- 3A press release, Exhibit 99.1, containing the detailed financial results is furnished with this report.
- 4Investors should consult the press release for specific performance metrics and commentary.
- 5The information in the press release is furnished and not deemed 'filed' for Section 18 purposes.
- 6The filing includes the cover page Interactive Data File in XBRL format.